My goodness!!
I wonder if the FDA will demand much more onerous tox studies if this ruling holds up?
Will still be important to perform efficacy trials, but with Cormasine Phase II might be enough to generate enough interest to really get sales moving. Note though the ruling apparently only applies where there is no other treatment. So even a useless one if available would close the loophole. Not sure there aren't (useless)treatments available for RCC and Melanoma already which would defeat this advantage for Cormasine?
- Forums
- ASX - By Stock
- re: fda approval
SBP
solbec pharmaceuticals limited
My goodness!!I wonder if the FDA will demand much more onerous...
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NRZ
NEURIZER LTD
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online